-
Understanding the mTOR Signaling Pathway: A Key Player in Cell Growth and Metabolism(Post)
Cell Signalling · MetabolismThe mTOR Signalling PathwaymTOR is a master regulator of cell growth, metabolism and survival, integrating nutrient, growth-factor and energy signals through two comp
SARS-CoV-2 테스트 키트 - 원스텝 RT-qPCR 키트(Post)SARS-CoV-2 검사 키트-코로나 바이러스 검사를위한 원스텝 RT-qPCR 키트 (2019-nCoV 종) 강력하고 재현 가능한 원스텝 코로나 바이러스 검사 (2019-nCoV종)
Anti-CTLA-4: Unleashing the Power of T Cells in Combination Immunotherapy(Post)Immunotherapy has revolutionized cancer treatment by harnessing the body's immune system to fight malignancies. Among the notable advancements in this field is the development of immune c
ELISA vs Western Blot: Which Technique Should You Choose?(Post)Written by Seán Mac Fhearraigh, PhD • Updated: 19 May 2026 • ~9 min read Quick Answer ELISA and Western Blot are both antibody-based protein detection methods. ELISA is faster, higher through
TMB Incubation Time in ELISA: Why It Makes or Breaks Results(Post)Quick answer A researcher ran a high-sensitivity porcine insulin sandwich ELISA on EDTA plasma and saw main-run duplicate CVs as high as 29.6% (kit spec: intra-assay CV <8%) togethe
Nod-Like Receptor Signaling Pathway: A Keystone in Innate Immunity(Post)The innate immune system, a primary line of defense against pathogens, comprises various cellular and molecular mechanisms. Among these, the Nod-like Receptor (NLR) signaling pathways play a criti
LAG-3: Revitalizing T Cells in Exhaustion for Combination Therapies(Post)Lymphocyte Activation Gene-3 (LAG-3) is an immune checkpoint receptor that plays a critical role in regulating T cell function. In recent years, LAG-3 has emerged as a potential target fo
Pembrolizumab: Unveiling Its Mechanism and Research Applications with Biosimilars(Post)Key Facts: PembrolizumabIs Pembrolizumab Safe?Pembrolizumab is widely recognized as safe for most patients, with side effects ranging from mild to severe. Commonly reported side effects
T4 DNA Ligase(Page) TAM and MDSC Signalling: Myeloid Reprogramming Pathway Guide(Post)In most solid tumours the largest immune population is not a T cell. It is a myeloid cell that has been recruited, expanded and re-educated by the tumour itself. Tumour-associated macrophages and mye
Relatlimab: Unlocking the Potential of LAG-3 Inhibition in Cancer Research(Post)Quick Facts About RelatlimabWhat is Relatlimab?Relatlimab is a monoclonal antibody that targets LAG-3 (Lymphocyte Activation Gene-3), a key immune checkpoint involved in T-cell regulatio
GeniePlex Multiplex Immunoassay FAQ(Page) Pancreatic Cancer and its Poor Prognosis(Post)Myrna Hurtado, PhD Student, University of North Texas Health Science Center Advancements in modern medicine have resulted in significantly prolonging and a
IHC Buffers & Recipes - Mandarin(Page)免疫组织化学缓冲液与配方(IHC,中文) | Assay Genie
Inflammasome Activation Pathways: A Comprehensive Overview(Post)Inflammasomes are complex intracellular structures that play a pivotal role in the immune response by detecting pathogenic microorganisms and sterile stressors. Their activation is a critical step
Apoptosis Assays(Page)Apoptosis Assay Kits | Caspase, Annexin V, TUNEL & JC-1 | Assay Genie
Anti-PD-L1: Targeting Tumor Evasion with Immune Checkpoint Blockade(Post)IntroductionCancer cells have developed sophisticated mechanisms to evade the immune system, particularly through the inhibition of T-cell responses. One such mechanism involves the progr
TIGIT: A New Frontier in Cancer and Autoimmune Disease Immunotherapy(Post)TIGIT (T cell immunoreceptor with Ig and ITIM domains) has emerged as a promising target in cancer immunotherapy and the treatment of autoimmune diseases. As a checkpoint receptor, TIGIT
Sofort anwendbar: Probenverdünnung berechnen für Laborpraxis(Post)Sofort anwendbar: Probenverdünnung berechnen für Laborpraxis Die Verdünnung berechnen Sie mit der Formel C1·V1 = C2·V2. Meist suchen Sie V1, also das Volumen der Ausgangslösung: V1 = (C2·V2)/C1. Wich
Vibostolimab: Mechanism, Clinical Applications, and Research Potential in Oncology(Post)Key Facts About VibostolimabWhat is Vibostolimab?Vibostolimab is an anti-TIGIT monoclonal antibody developed by Merck, targeting immune checkpoint pathways to enhance anti-tumor immunity